One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) saw unusually large options trading on Monday. Stock investors acquired 31,516 call options on the stock. This is an increase of 87% compared ...

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $23.91, marking a -0.99% move from the previous day.

Viking Therapeutics (NasdaqCM:VKTX) has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zentalis Pharmaceuticals (ZNTL – Research ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus rating of “Buy” by the thirteen research ...